Notably, treatment with anti-PD-1 in nlrp3−/− mice resulted in near complete tumor abrogation at day 21 (p < 0.01) with significant reduction compared to monotherapy anti-PD-1 or nlrp3−/− mice alone (p < 0.05) (Figure 4B). The gene discussed is NLRP3; the disease is neoplasm.